Dr. Joseph Mikhael, Chief Medical Officer at the International Myeloma Foundation, highlights an ASCO 2018 session about monoclonal antibodies used to treat multiple myeloma. Dr. Mikhael comments on the following:
- The use of monoclonal antibodies are significant for myeloma patients at first relapse.
- Monoclonal antibodies may be used in combination with lenalidomide, bortezomib, and other agents to help a patient reach remission.
- Treatment with monoclonal antibodies must be individualized due to myeloma’s complexities.
In addition, Dr. Mikhael previews the use of new monoclonal antibodies and other new treatments, including CAR T-cell therapy.